Galectin Therapeutics (GALT) Misses Q2 EPS by 4c

Galectin Therapeutics (NASDAQ: GALT) reported Q2 EPS of ($0.20), $0.04 worse than the analyst estimate of ($0.16).

For earnings history and earnings-related data on Galectin Therapeutics (GALT) click here.

You May Also Be Interested In

• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Nlight (LASR) Reiterated at Buy by Stifel: Sell-off is a 'Buying Opportunity'
• Sysco adds two directors, targets AI-driven cost savings of $100M